AU2014262890B2 - Treatment of Alzheimer's disease subpopulations with pooled immunoglobulin G - Google Patents

Treatment of Alzheimer's disease subpopulations with pooled immunoglobulin G Download PDF

Info

Publication number
AU2014262890B2
AU2014262890B2 AU2014262890A AU2014262890A AU2014262890B2 AU 2014262890 B2 AU2014262890 B2 AU 2014262890B2 AU 2014262890 A AU2014262890 A AU 2014262890A AU 2014262890 A AU2014262890 A AU 2014262890A AU 2014262890 B2 AU2014262890 B2 AU 2014262890B2
Authority
AU
Australia
Prior art keywords
subject
igg
alzheimer
administered
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014262890A
Other languages
English (en)
Other versions
AU2014262890A1 (en
Inventor
Sandor Fritsch
David M. Gelmont
Hans-Peter Schwarz
Julia Singer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2014262890A1 publication Critical patent/AU2014262890A1/en
Application granted granted Critical
Publication of AU2014262890B2 publication Critical patent/AU2014262890B2/en
Priority to AU2019202459A priority Critical patent/AU2019202459B2/en
Priority to AU2020257034A priority patent/AU2020257034A1/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: Baxalta GmbH, BAXALTA INCORPORATED
Priority to AU2024201051A priority patent/AU2024201051A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2014262890A 2013-05-06 2014-05-05 Treatment of Alzheimer's disease subpopulations with pooled immunoglobulin G Active AU2014262890B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2019202459A AU2019202459B2 (en) 2013-05-06 2019-04-09 Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
AU2020257034A AU2020257034A1 (en) 2013-05-06 2020-10-19 Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
AU2024201051A AU2024201051A1 (en) 2013-05-06 2024-02-19 Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361855062P 2013-05-06 2013-05-06
US61/855,062 2013-05-06
US201361833447P 2013-06-10 2013-06-10
US61/833,447 2013-06-10
US201361844732P 2013-07-10 2013-07-10
US61/844,732 2013-07-10
US201361886464P 2013-10-03 2013-10-03
US61/886,464 2013-10-03
PCT/US2014/036848 WO2014182631A1 (en) 2013-05-06 2014-05-05 Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019202459A Division AU2019202459B2 (en) 2013-05-06 2019-04-09 Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g

Publications (2)

Publication Number Publication Date
AU2014262890A1 AU2014262890A1 (en) 2015-11-26
AU2014262890B2 true AU2014262890B2 (en) 2019-01-31

Family

ID=50943566

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2014262890A Active AU2014262890B2 (en) 2013-05-06 2014-05-05 Treatment of Alzheimer's disease subpopulations with pooled immunoglobulin G
AU2019202459A Active AU2019202459B2 (en) 2013-05-06 2019-04-09 Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
AU2020257034A Abandoned AU2020257034A1 (en) 2013-05-06 2020-10-19 Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
AU2024201051A Pending AU2024201051A1 (en) 2013-05-06 2024-02-19 Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2019202459A Active AU2019202459B2 (en) 2013-05-06 2019-04-09 Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
AU2020257034A Abandoned AU2020257034A1 (en) 2013-05-06 2020-10-19 Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
AU2024201051A Pending AU2024201051A1 (en) 2013-05-06 2024-02-19 Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g

Country Status (12)

Country Link
US (3) US20140328856A1 (enExample)
EP (2) EP2994160B1 (enExample)
JP (1) JP6424210B2 (enExample)
AU (4) AU2014262890B2 (enExample)
DK (1) DK2994160T3 (enExample)
ES (1) ES2740127T3 (enExample)
HR (1) HRP20191383T1 (enExample)
HU (1) HUE044737T2 (enExample)
LT (1) LT2994160T (enExample)
PL (1) PL2994160T3 (enExample)
PT (1) PT2994160T (enExample)
WO (1) WO2014182631A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4289820A3 (en) 2014-03-21 2024-03-13 Alzheon, Inc. Compounds for use in treating alzheimer's disease in apoe4+/+ patients
WO2016033382A1 (en) * 2014-08-27 2016-03-03 Capnia, Inc. Methods for immune globulin administration
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JP6789579B2 (ja) * 2015-09-10 2020-11-25 アルジオン， インコーポレイテッド 特定の患者集団において神経変性障害を処置する方法
CN114019170A (zh) * 2016-01-20 2022-02-08 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
HRP20211628T1 (hr) * 2016-08-18 2022-02-04 Alkahest, Inc. Frakcije krvne plazme kao tretman za kongitivne poremećaje povezane sa starenjem
BR112019022402A2 (pt) * 2017-04-26 2020-05-19 Alkahest Inc regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
SI3672631T1 (sl) 2017-08-22 2023-06-30 Biogen Ma Inc. Farmacevtski sestavki, ki vsebujejo protitelesa proti beta amiloidu
FI128916B (en) * 2018-02-05 2021-03-15 Vetcare Oy Health-promoting composition and method for its preparation
KR102276545B1 (ko) * 2019-09-05 2021-07-15 고려대학교 산학협력단 Ct 영상 기반 부위별 대뇌 피질 수축율 예측 방법 및 장치
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
CA3198827A1 (en) * 2020-10-30 2022-05-05 Rush University Medical Center Intranasal immunotherapy for the treatment of alzheimer's disease
EP4472679A1 (en) * 2022-02-03 2024-12-11 Eli Lilly and Company Regional tau imaging for diagnosing and treating alzheimer's disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110251479A1 (en) * 2010-04-13 2011-10-13 Baxter International Inc. Use of ventricular enlargement rate in intravenous immunoglobulin treatment of alzheimer's disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (enExample) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
WO2003028668A2 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. Gammaglobulin treatment of immune disorders
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
WO2006091332A2 (en) 2005-02-23 2006-08-31 Alza Corporation Intranasal administration of active agents to the central nervous system
PL1981540T3 (pl) * 2006-01-30 2013-08-30 Grifols Therapeutics Inc Sposób leczenia i profilaktyki chorób związanych z odkładaniem się amyloidu z zastosowaniem IgM
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US9084743B2 (en) 2009-09-17 2015-07-21 Baxter International Inc. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
US8622993B2 (en) 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
WO2011142778A1 (en) * 2010-05-13 2011-11-17 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
JP6055412B2 (ja) * 2010-09-17 2016-12-27 バクスアルタ ゲーエムベーハー 弱酸性〜中性のｐＨにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化
KR20130139153A (ko) * 2011-01-18 2013-12-20 백스터 인터내셔널 인코포레이티드 인간 혈액 중 항-베타 아밀로이드 항체의 측정
US20120251524A1 (en) * 2011-04-01 2012-10-04 Baxter Healthcare S.A. Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease
ES2714999T3 (es) * 2011-09-24 2019-05-31 Csl Behring Gmbh Terapia de combinación que usa inmunoglobulina e inhibidor de C1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110251479A1 (en) * 2010-04-13 2011-10-13 Baxter International Inc. Use of ventricular enlargement rate in intravenous immunoglobulin treatment of alzheimer's disease

Also Published As

Publication number Publication date
AU2014262890A1 (en) 2015-11-26
PL2994160T3 (pl) 2019-10-31
JP6424210B2 (ja) 2018-11-14
AU2019202459A1 (en) 2019-05-02
AU2024201051A1 (en) 2024-03-14
HRP20191383T1 (hr) 2020-02-07
ES2740127T3 (es) 2020-02-05
LT2994160T (lt) 2019-08-26
DK2994160T3 (da) 2019-08-12
US20140328856A1 (en) 2014-11-06
US20210238267A1 (en) 2021-08-05
EP2994160B1 (en) 2019-07-03
AU2020257034A1 (en) 2020-11-12
WO2014182631A1 (en) 2014-11-13
EP3552624A1 (en) 2019-10-16
EP2994160A1 (en) 2016-03-16
JP2016518411A (ja) 2016-06-23
US20190144530A1 (en) 2019-05-16
HUE044737T2 (hu) 2019-11-28
AU2019202459B2 (en) 2020-07-23
PT2994160T (pt) 2019-08-07

Similar Documents

Publication Publication Date Title
AU2019202459B2 (en) Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
US11851481B2 (en) Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
US11214621B2 (en) Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
JP2015532592A5 (enExample)
JP6746495B2 (ja) ベンラリツマブを使用して喘息の増悪率を低減する方法
TW201420116A (zh) 投與ｉｌ－４ｒ拮抗劑以治療或預防氣喘之方法
US11147873B2 (en) Treatment of Alzheimer's Disease (AD) with an aluminum salt
CN111741768B (zh) 治疗IgE介导的过敏性疾病
HK40015677A (en) Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g
CA2946931A1 (en) Treatment and prevention of alzheimer's disease (ad)
AU2024202756A1 (en) Treatment of central nervous system disorders by intranasal administration of immunoglobulin g

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): BAXALTA GMBH; BAXALTA INCORPORATED